IBS is an extremely common functional disorder affecting between 15 percent and 20 percent of all people in the United States. This clinical case study was conducted to determine the potential of a multispecies probiotic supplement, Multi-Flora Plus (manufactured by UAS Laboratories Inc.) in the treatment of irritable bowel syndrome (IBS).
Patients (n=25) aged 25 to 86 years with chronic IBS, were selected using the Rome III criteria and treated with probiotic supplement containing special Lactobacillus acidophilus DDS-1 strain, Bifidobacterium bifidum, Bifidobacterium longum and Bifidobacterium lactis with fructooligosaccharide in a dose of 12 Billion CFU/g (two capsules) daily for two months.
Patients were evaluated at the beginning of the study, after one month, and after two months of treatment. The most significant improvement in symptoms occurred after two months of treatment with 84 percent of the patients showing improvement in abdominal pain, 73.9 percent in bloating, 92 percent in belching, 88 percent in flatulence, 90.9 percent in diarrhea, and 86.9 percent in constipation.
These results were based upon at least 50 percent improvement in symptoms from the time of starting therapy with probiotic supplement. In addition, no clinically evident side effects from the use of Multi-Flora Plus probiotic were reported. Further clinical studies are needed to reconfirm the positive effects of probiotics on IBS.
For more research, visit www.ChiroEco.com/ccr3UASlabs.
This research was provided by UAS Laboratories Inc.
952-935-1701 * www.uaslabs.com